Biodexa Pharmaceuticals Advances FAP Treatment

Biodexa Pharmaceuticals (BDRX) has released an update.

Biodexa Pharmaceuticals PLC has successfully made a $3 million payment, unlocking the remaining funds from a $17 million grant by the Cancer Prevention Research Institute of Texas (CPRIT) for its Phase 3 study of eRapa in treating Familial Adenomatous Polyposis (FAP). This advancement is significant as FAP, a condition leading to a high risk of colon cancer due to precancerous polyps, affects around 100,000 patients in the U.S. and Europe with no approved drugs currently available. The company’s commitment to addressing unmet medical needs is underscored by promising Phase 2 results showing a median polyp burden reduction and a high non-progression rate, setting the stage for the upcoming Phase 3 trial.

For further insights into BDRX stock, check out TipRanks’ Stock Analysis page.